I've watched labs with massive throughput opportunity — demand that would fill their sequencers and justify their capital investment — sit on the sidelines because leadership won't approve the expansion. Not because the technology failed. Not because the lab can't execute. But because the accumulated weight of years of architectural decisions made the overhead per sample so high that scaling doesn't deliver acceptable ROI.
That's not a technology problem. It's a technical debt problem. And it's compounding silently — one defensible decision at a time — until the lab can't grow without rebuilding what it already has.
The high-throughput sequencing platform sits at 40% utilization. The LIMS is live. The demand exists. But leadership sees a cost center with inefficient infrastructure that can't absorb additional throughput without hemorrhaging OpEx. So the opportunity sits there, untouched, while expensive capital equipment runs well below capacity — and the lab stays locked at current volume.
How technical debt accumulates
Laboratory technical debt doesn't announce itself. It accumulates quietly, one defensible decision at a time, over years. Each choice made sense in isolation. The cumulative effect is a lab that gets harder to operate, harder to scale, and harder to justify to leadership with every passing year. The four scenarios below are composited from real labs — different vendors, different modalities, same compounding mechanism.
Lab does molecular diagnostics, clinical chemistry, and microbiology. Leadership buys a single "comprehensive" LIMS to cover all three modalities. Budget justification is clean: one vendor, one contract, one support relationship.
The platform works well for routine clinical testing. But the molecular NGS workflow doesn't fit. Sample tracking is too rigid. Batch management doesn't support the flexibility NGS requires. Index assignment is clunky. Reporting templates can't handle the complexity of variant interpretation and re-classification.
So the lab hires a contractor to build the gap. Custom code bridges the workflow mismatch. It works. The contractor leaves.
Five years later: the lab needs to modify the workflow. The original code author is long gone. Little documentation exists, and the vendor won't support custom modifications. The lab discovers it owns the liability but not the knowledge to maintain it.
Lab buys a liquid handler that doesn't support API integration. Manual export to CSV is fine at the time — staff can upload the file to the LIMS without too much friction.
At 5,000 samples per year, manual export is tolerable. At 15,000 samples per year, data entry errors accumulate, staff burn out on repetitive manual tasks, and turnaround time slips. The bottleneck is now the thing that was supposed to automate the bottleneck.
The lab can't automate the handoff without replacing a $200K instrument that still works perfectly well — for the volume it was purchased to handle.
Lab implements an end-to-end workflow using a modern event-streaming platform like Kafka as the backbone. The architecture is clean on paper: every system in the chain — LIMS, sequencer, bioinformatics pipeline, LIS, EMR — emits events that downstream systems subscribe to as needed. The whole workflow becomes loosely coupled and traceable end-to-end. The lab's IT lead has experience with the technology. The choice is well-defended in design review.
The architecture works. The lab can trace a sample's journey end-to-end. New systems can be added without rebuilding old ones. What the lab didn't model: running this kind of platform reliably is its own engineering discipline. It requires a sustained level of in-house expertise to operate, evolve, and troubleshoot — expertise that has to be retained as people come and go.
Three years later: the IT lead who designed the system has moved on. The replacement IT team can keep things running but doesn't have the same depth. New workflows that used to take weeks now take months because nobody fully understands the existing design. Adding a new system means reverse-engineering decisions that were made years ago by people no longer at the lab. The architecture decision was right for a lab with sustained platform engineering capacity. This lab didn't build that capacity until it was too late.
Lab chooses on-premise deployment for the LIMS. Makes sense at 5,000 samples per year. Control, security, no ongoing cloud fees.
Now doing 15,000 samples per year. The OpEx for maintaining on-premise infrastructure — servers, backups, IT staff, security patches, disaster recovery — is three times what an equivalent cloud deployment would cost. Worse: the sequencing platform could handle 3x current volume, but the infrastructure overhead makes scaling uneconomical. Expensive capital equipment running at less than half capacity.
Migration to cloud would require three months of revalidation and workflow downtime the lab can't afford. The lab is locked into the on-premise architecture, paying enterprise OpEx for a deployment model the volume no longer justifies.
Why it compounds invisibly
None of these decisions were wrong when they were made. The LIMS covered three modalities. The liquid handler automated a manual process. The sequencer included cloud analysis. The on-premise deployment gave the lab control. Each choice was rational. Each closed an immediate gap.
But they were made in isolation — without modeling how they would interact with future growth, future systems, or future operational reality. The debt compounds when these decisions stack on top of each other, creating a workflow that's brittle, expensive to maintain, and impossible to modify without breaking something else.
Three failure modes show up over and over. Together they explain why labs that look fine on the operational dashboard can be one event away from a serious problem.
Single points of failure in the workflow
The custom code is a problem. The bigger problem is that the custom code — and in some cases entire systems in the end-to-end workflow — depends on a single individual. When that person leaves, there is no cross-training, no contingency plan, and often no backfill ready to take on the work.
The pattern is recognizable: the senior tech who is the only one who knows how the LIS interface actually works. The bioinformatician who wrote all the analysis scripts with no documentation and no version control. The IT contractor who configured the middleware, left two years ago, and produced no handoff documentation. The lab manager who manually reconciles LIS/LIMS discrepancies every morning on tribal knowledge alone.
One person quits. The critical workflow breaks. The lab scrambles to hire a replacement, can't onboard the new hire without the original employee's knowledge, and ends up paying outside consultants to reverse-engineer what the previous employee built. Then the cycle repeats with the next hire. This isn't a staffing problem. It's a knowledge management problem. Labs that don't document systems, cross-train staff, and build redundancy into critical workflow steps are one resignation letter away from operational crisis.
The vendor support cliff
The vendor had your back when the system was first deployed. They held your hand through go-live, answered every support ticket, sent engineers on-site for troubleshooting. Three years later the relationship feels different. The support contract costs the same, but the responsiveness isn't what it was. And somewhere along the way, you realized: the ultimate responsibility for your end-to-end operations falls on you, not them.
The erosion runs predictably. In year one, the vendor implementation team is hands-on and invested. By year two, support transitions to tier-one help desk and response times slow. By year three, the answer becomes "that's a custom configuration — we don't support that." By year four, every issue requires a professional services quote. By year five, the lab realizes it's paying for support it can't actually use.
Labs become dependent on vendor professional services for routine maintenance. Not because the work is inherently complex — but because nobody internally was trained to do it, and the vendor has no commercial incentive to make the system easier for the lab to maintain independently. Every configuration change, every workflow modification, every troubleshooting session becomes a line item the lab didn't budget for.
Underutilized capital equipment
The most expensive outcome of all: high-throughput platforms sitting underutilized because the infrastructure around them can't support the volume the equipment was designed to handle. Labs that invested six or seven figures in sequencing capacity running at 40% utilization — not because demand doesn't exist, but because the overhead per sample makes growth uneconomical.
Leadership sees the utilization number. Leadership sees the OpEx trajectory if the lab tries to grow. Leadership concludes the lab isn't a growth investment. The capital sits idle while demand routes elsewhere. The longer this lasts, the harder it is to make the case for the modernization that would unlock the capacity.
The learned helplessness trap
Talking to lab leaders about technical debt, I hear the same response more than any other:
"This is just the way it is. Everyone deals with this. There's nothing we can do about it."
That's learned helplessness. And it's the most expensive mindset a lab can adopt — because it stops the team from even attempting to fix the problem.
The mindset shows up in concrete forms: "Our LIMS is too customized to migrate." "We can't upgrade without breaking everything." "The vendor won't help us." "We don't have the staff to document this." "It's working well enough — why risk breaking it?" Each of these statements may be partially true on a given day. None of them is permanently true. They're all symptoms of an organization that has stopped asking the harder question: what would it actually take to fix this?
Labs can turn this around. But it requires two things most labs aren't willing to commit to: a frank assessment of current state, and a willingness to endure short-term pain to achieve a more stable, scalable outcome.
The path out
The way out of technical debt isn't a single project or a single vendor. It's a deliberate, multi-year effort to reduce brittleness, build redundancy, and regain operational control. It starts with honesty.
Inventory the systems and decisions that compound your operational risk. Which systems are dependent on a single person? What custom code exists, who wrote it, and is it documented? What equipment can't integrate with newer systems? What vendor contracts constrain your options? What architectural decisions are costing you OpEx every month?
Not all technical debt is equal. Some constraints hurt more than others. Ask: what breaks first if a key person quits tomorrow? What constraint keeps you from scaling? What costs you the most in ongoing professional services? Fix the highest-pain item first, not the easiest one. Easy wins don't compound; expensive constraints do.
Fixing technical debt isn't free, and it isn't fast. Documenting undocumented systems takes time. Cross-training staff takes time. Migrating from on-premise to cloud requires validation downtime. Replacing equipment means capital expense. Short-term pain is the price of long-term stability. Labs that refuse to endure it stay locked in the pattern indefinitely.
When you do make changes — whether replacing equipment, migrating platforms, or adding new systems — design for the lab you're becoming, not the lab you are today. Choose platforms with documented APIs over proprietary interfaces. Invest in cloud-first infrastructure where it makes operational sense. Require vendor handoff documentation as part of every implementation contract. Document everything. Cross-train everyone.
Leadership won't approve infrastructure modernization just because it makes operations easier. They'll approve it when you can show the ROI — and that starts with quantifying what technical debt is costing you right now. Translate the audit into a sequenced, business-cased roadmap that frames remediation as asset-utilization recovery and OpEx reduction, not as a maintenance project.
Who pays for technical debt
Laboratory technical debt creates costs for almost everyone with a stake in the lab's success. The lab leader pays in operational burden, manual workarounds, single points of failure, increased professional services fees, inefficient infrastructure, and staff burnout from doing work that should be automated. The lab itself pays in reduced agility, the inability to adopt new technologies without breaking existing workflows, and underutilized capital equipment that should have already paid for itself. The vendor pays too, even when it doesn't realize it: delayed onboarding, missed launch targets, support resources tied up maintaining custom configurations rather than building new product capability.
The party that consistently benefits is whoever bills the lab indefinitely to maintain a system that should have been designed to operate independently. If your lab is paying outside help to maintain its end-to-end workflow indefinitely, the question worth asking is straightforward: is this the outcome you wanted when you bought the platform?
Because the answer matters. That's not a technology success story — it's a business model your lab is funding, built out of decisions nobody made but everybody now lives with. The path out doesn't start with another vendor selection. It starts with the structured audit of what you've already accumulated, and the discipline to fix the highest-pain item first.
Founder, HelixWrks Advisory. 12+ years spanning clinical genomics data, molecular IVD implementation, and software product strategy across LIMS, lab automation middleware, LIS/EHR integration architecture, and end-to-end workflow strategy. Decision-point only — not implementation, configuration, or integration execution.